Evaluar	O
la	O
seguridad	O
,	O
la	O
tolerabilidad	O
y	O
la	O
eficacia	O
de	O
abatacept	O
en	O
pacientes	O
con	O
artritis	O
reumatoide	O
(	O
AR	O
)	O
que	O
no	O
respondieron	O
al	O
tratamiento	O
con	O
factor	O
de	O
necrosis	O
tumoral	O
(	O
TNF	O
)	O
y	O
cambiaron	O
a	O
abatacept	O
directamente	O
o	O
después	O
de	O
completar	O
el	O
lavado	O
.	O

En	O
este	O
ensayo	O
abierto	O
internacional	O
de	O
6	O
meses	O
,	O
los	O
pacientes	O
tenían	O
AR	O
activa	O
,	O
una	O
respuesta	O
inadecuada	O
a	O
la	O
terapia	O
anti	O
-	O
TNF	O
durante	O
3	O
meses	O
o	O
más	O
y	O
una	O
puntuación	O
de	O
actividad	O
de	O
la	O
enfermedad	O
en	O
28	O
articulaciones	O
(	O
DAS28	O
(	O
proteína	O
C	O
reactiva	O
,	O
PCR	O
)	O
de	O
5.1	O
o	O
superior	O
.	O

Los	O
pacientes	O
de	O
``	O
lavado	O
''	O
interrumpieron	O
la	O
terapia	O
anti-TNF	O
durante	O
2	O
meses	O
o	O
más	O
antes	O
de	O
la	O
selección	O
;	O
Los	O
pacientes	O
del	O
``	O
cambio	O
directo	O
''	O
comenzaron	O
con	O
abatacept	O
(	O
aproximadamente	O
10	O
mg/kg	O
)	O
en	O
su	O
próxima	O
dosis	O
programada	O
de	O
terapia	O
anti-TNF	O
.	O

Se	O
trataron	O
1046	O
pacientes	O
(	O
449	O
con	O
lavado	O
,	O
597	O
con	O
cambio	O
directo	O
;	O
las	O
características	O
basales	O
fueron	O
similares	O
entre	O
los	O
grupos	O
)	O
.	O

A	B-Premise-Support-3-Support-4
los	I-Premise-Support-3-Support-4
6	I-Premise-Support-3-Support-4
meses	I-Premise-Support-3-Support-4
,	I-Premise-Support-3-Support-4
los	I-Premise-Support-3-Support-4
eventos	I-Premise-Support-3-Support-4
adversos	I-Premise-Support-3-Support-4
(	I-Premise-Support-3-Support-4
EA	I-Premise-Support-3-Support-4
;	I-Premise-Support-3-Support-4
78,0	I-Premise-Support-3-Support-4
%	I-Premise-Support-3-Support-4
frente	I-Premise-Support-3-Support-4
a	I-Premise-Support-3-Support-4
79,2	I-Premise-Support-3-Support-4
%	I-Premise-Support-3-Support-4
)	I-Premise-Support-3-Support-4
,	I-Premise-Support-3-Support-4
EA	I-Premise-Support-3-Support-4
graves	I-Premise-Support-3-Support-4
(	I-Premise-Support-3-Support-4
11,1	I-Premise-Support-3-Support-4
%	I-Premise-Support-3-Support-4
frente	I-Premise-Support-3-Support-4
a	I-Premise-Support-3-Support-4
9,9	I-Premise-Support-3-Support-4
%	I-Premise-Support-3-Support-4
)	I-Premise-Support-3-Support-4
e	I-Premise-Support-3-Support-4
interrupciones	I-Premise-Support-3-Support-4
debido	I-Premise-Support-3-Support-4
a	I-Premise-Support-3-Support-4
EA	I-Premise-Support-3-Support-4
(	I-Premise-Support-3-Support-4
3,8	I-Premise-Support-3-Support-4
%	I-Premise-Support-3-Support-4
frente	I-Premise-Support-3-Support-4
a	I-Premise-Support-3-Support-4
4,0	I-Premise-Support-3-Support-4
%	I-Premise-Support-3-Support-4
)	I-Premise-Support-3-Support-4
y	I-Premise-Support-3-Support-4
EA	I-Premise-Support-3-Support-4
graves	I-Premise-Support-3-Support-4
(	I-Premise-Support-3-Support-4
2,0	I-Premise-Support-3-Support-4
%	I-Premise-Support-3-Support-4
frente	I-Premise-Support-3-Support-4
a	I-Premise-Support-3-Support-4
1,3	I-Premise-Support-3-Support-4
%	I-Premise-Support-3-Support-4
)	I-Premise-Support-3-Support-4
fueron	I-Premise-Support-3-Support-4
comparables	I-Premise-Support-3-Support-4
en	I-Premise-Support-3-Support-4
pacientes	I-Premise-Support-3-Support-4
con	I-Premise-Support-3-Support-4
lavado	I-Premise-Support-3-Support-4
versus	I-Premise-Support-3-Support-4
pacientes	I-Premise-Support-3-Support-4
con	I-Premise-Support-3-Support-4
cambio	I-Premise-Support-3-Support-4
directo	I-Premise-Support-3-Support-4
.	I-Premise-Support-3-Support-4

No	B-Premise-Support-2
hubo	I-Premise-Support-2
infecciones	I-Premise-Support-2
oportunistas	I-Premise-Support-2
.	I-Premise-Support-2

A	B-Premise-Support-1-Support-2
los	I-Premise-Support-1-Support-2
6	I-Premise-Support-1-Support-2
meses	I-Premise-Support-1-Support-2
,	I-Premise-Support-1-Support-2
en	I-Premise-Support-1-Support-2
pacientes	I-Premise-Support-1-Support-2
con	I-Premise-Support-1-Support-2
lavado	I-Premise-Support-1-Support-2
versus	I-Premise-Support-1-Support-2
cambio	I-Premise-Support-1-Support-2
directo	I-Premise-Support-1-Support-2
,	I-Premise-Support-1-Support-2
se	I-Premise-Support-1-Support-2
observaron	I-Premise-Support-1-Support-2
mejoras	I-Premise-Support-1-Support-2
clínicamente	I-Premise-Support-1-Support-2
significativas	I-Premise-Support-1-Support-2
similares	I-Premise-Support-1-Support-2
en	I-Premise-Support-1-Support-2
DAS28	I-Premise-Support-1-Support-2
(	I-Premise-Support-1-Support-2
PCR	I-Premise-Support-1-Support-2
)	I-Premise-Support-1-Support-2
(	I-Premise-Support-1-Support-2
mejora	I-Premise-Support-1-Support-2
>	I-Premise-Support-1-Support-2
o	I-Premise-Support-1-Support-2
=	I-Premise-Support-1-Support-2
1,2	I-Premise-Support-1-Support-2
unidades	I-Premise-Support-1-Support-2
,	I-Premise-Support-1-Support-2
59,5	I-Premise-Support-1-Support-2
%	I-Premise-Support-1-Support-2
frente	I-Premise-Support-1-Support-2
a	I-Premise-Support-1-Support-2
53,6	I-Premise-Support-1-Support-2
%	I-Premise-Support-1-Support-2
,	I-Premise-Support-1-Support-2
respectivamente	I-Premise-Support-1-Support-2
;	I-Premise-Support-1-Support-2
estado	I-Premise-Support-1-Support-2
de	I-Premise-Support-1-Support-2
baja	I-Premise-Support-1-Support-2
actividad	I-Premise-Support-1-Support-2
de	I-Premise-Support-1-Support-2
la	I-Premise-Support-1-Support-2
enfermedad	I-Premise-Support-1-Support-2
,	I-Premise-Support-1-Support-2
22,5	I-Premise-Support-1-Support-2
%	I-Premise-Support-1-Support-2
frente	I-Premise-Support-1-Support-2
a	I-Premise-Support-1-Support-2
22,3	I-Premise-Support-1-Support-2
%	I-Premise-Support-1-Support-2
;	I-Premise-Support-1-Support-2
remisión	I-Premise-Support-1-Support-2
definida	I-Premise-Support-1-Support-2
por	I-Premise-Support-1-Support-2
DAS28	I-Premise-Support-1-Support-2
,	I-Premise-Support-1-Support-2
12,0	I-Premise-Support-1-Support-2
%	I-Premise-Support-1-Support-2
frente	I-Premise-Support-1-Support-2
a	I-Premise-Support-1-Support-2
13,7	I-Premise-Support-1-Support-2
%	I-Premise-Support-1-Support-2
)	I-Premise-Support-1-Support-2
,	I-Premise-Support-1-Support-2
función	I-Premise-Support-1-Support-2
física	I-Premise-Support-1-Support-2
(	I-Premise-Support-1-Support-2
índice	I-Premise-Support-1-Support-2
de	I-Premise-Support-1-Support-2
discapacidad	I-Premise-Support-1-Support-2
del	I-Premise-Support-1-Support-2
cuestionario	I-Premise-Support-1-Support-2
de	I-Premise-Support-1-Support-2
evaluación	I-Premise-Support-1-Support-2
de	I-Premise-Support-1-Support-2
la	I-Premise-Support-1-Support-2
salud	I-Premise-Support-1-Support-2
>	I-Premise-Support-1-Support-2
o	I-Premise-Support-1-Support-2
=	I-Premise-Support-1-Support-2
0,22	I-Premise-Support-1-Support-2
de	I-Premise-Support-1-Support-2
mejora	I-Premise-Support-1-Support-2
;	I-Premise-Support-1-Support-2
46,3	I-Premise-Support-1-Support-2
%	I-Premise-Support-1-Support-2
frente	I-Premise-Support-1-Support-2
a	I-Premise-Support-1-Support-2
47,1	I-Premise-Support-1-Support-2
%	I-Premise-Support-1-Support-2
)	I-Premise-Support-1-Support-2
y	I-Premise-Support-1-Support-2
calidad	I-Premise-Support-1-Support-2
de	I-Premise-Support-1-Support-2
vida	I-Premise-Support-1-Support-2
relacionada	I-Premise-Support-1-Support-2
con	I-Premise-Support-1-Support-2
la	I-Premise-Support-1-Support-2
salud	I-Premise-Support-1-Support-2
(	I-Premise-Support-1-Support-2
cambio	I-Premise-Support-1-Support-2
medio	I-Premise-Support-1-Support-2
en	I-Premise-Support-1-Support-2
las	I-Premise-Support-1-Support-2
puntuaciones	I-Premise-Support-1-Support-2
de	I-Premise-Support-1-Support-2
la	I-Premise-Support-1-Support-2
forma	I-Premise-Support-1-Support-2
abreviada	I-Premise-Support-1-Support-2
36	I-Premise-Support-1-Support-2
:	I-Premise-Support-1-Support-2
física	I-Premise-Support-1-Support-2
resumen	I-Premise-Support-1-Support-2
de	I-Premise-Support-1-Support-2
componentes	I-Premise-Support-1-Support-2
,	I-Premise-Support-1-Support-2
5,5	I-Premise-Support-1-Support-2
frente	I-Premise-Support-1-Support-2
a	I-Premise-Support-1-Support-2
6,1	I-Premise-Support-1-Support-2
,	I-Premise-Support-1-Support-2
resumen	I-Premise-Support-1-Support-2
de	I-Premise-Support-1-Support-2
componentes	I-Premise-Support-1-Support-2
mentales	I-Premise-Support-1-Support-2
,	I-Premise-Support-1-Support-2
4,8	I-Premise-Support-1-Support-2
frente	I-Premise-Support-1-Support-2
a	I-Premise-Support-1-Support-2
5,4	I-Premise-Support-1-Support-2
)	I-Premise-Support-1-Support-2
.	I-Premise-Support-1-Support-2

Abatacept	B-Claim
demostró	I-Claim
una	I-Claim
seguridad	I-Claim
y	I-Claim
tolerabilidad	I-Claim
aceptables	I-Claim
y	I-Claim
una	I-Claim
eficacia	I-Claim
clínicamente	I-Claim
significativa	I-Claim
durante	I-Claim
6	I-Claim
meses	I-Claim
en	I-Claim
pacientes	I-Claim
con	I-Claim
respuesta	I-Claim
inadecuada	I-Claim
a	I-Claim
la	I-Claim
terapia	I-Claim
anti-TNF	I-Claim
.	I-Claim

Los	O
resultados	B-Claim
fueron	I-Claim
comparables	I-Claim
con	I-Claim
o	I-Claim
sin	I-Claim
lavado	I-Claim
,	I-Claim
lo	I-Claim
que	I-Claim
respalda	I-Claim
el	I-Claim
cambio	I-Claim
directo	I-Claim
de	I-Claim
la	I-Claim
terapia	I-Claim
anti-TNF	I-Claim
a	I-Claim
abatacept	I-Claim
como	I-Claim
una	I-Claim
opción	I-Claim
en	I-Claim
la	I-Claim
práctica	I-Claim
clínica	I-Claim
.	I-Claim

